LITSHealthcare · Biotechnology

LITS Stock Forecast: Lite Strategy, Inc. Price Predictions for 2026-2027

Last close, 3 Aug 2026

$0.98

+2.21% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 30 of 100 as at 1 Aug 2026 — in the lower half.

Market cap

$32.8M

Ticker Nerd rank

30 / 100

Median analyst target

—

Analysts covering

—

Total return, dividends reinvested

+0.1%

+3.3%

YTD

−25.7%

−79.9%

From 52W high

−81.4%

From 52W low

+32.6%

$0.74

$5.28

52-week range, adjusted closes · the dot is the last close

Ticker Nerd rank

LITS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Lite Strategy, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 1 Aug 2026

30 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth

Size

Volatility

Accruals

Quality

Issuance

Revisions

Value

Momentum

Growth (85): Sales and profits are climbing, and climbing faster than before.

Momentum (7): The shares have been drifting down relative to others.

The rank is the raw material. Whether the rules would actually own Lite Strategy, Inc. — and when they’d sell — is the membership.

Wall Street

LITS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LITS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

LITS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Lite Strategy, Inc. (LITS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation

Trailing P/E: −0.4×
Price / sales: —
Price / book: 0.6×
EV / EBITDA: −1.5×

Growth & margins

Revenue growth (YoY): —
Earnings growth (YoY): —
Gross margin: —
Operating margin: 0.0%
Net margin: 0.0%

Returns & dividend

Return on equity: −159.3%
Return on assets: −27.7%
Dividend yield: —

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LITS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology

Company	Market cap	TKN rank
LITSLite Strategy, Inc.	$32.8M	30
NTRBNutriband, Inc.	$34.3M	17
CRVOCervoMed, Inc.	$34.9M	22
LTRNLantern Pharma, Inc.	$33.6M	68
ENLVEnlivex Ltd.	$35.2M	22
VERUVeru, Inc.	$36.0M	46
PDSBPDS Biotechnology Corp.	$37.5M	59

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LITS appears on the weeks it earns a place.

News

Latest LITS news & analysis

Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share

GlobeNewsWire · 30 July 2026positive

Lite Strategy repurchased approximately 4.9 million shares, or 13% of its outstanding shares, under its Share Repurchase Program between December 2025 and July 17, 2026, deploying about $5.4 million at an average price of $1.11 per share through treasury operations.

Why it matters — A LITS watcher would care because the buyback reduces the total share count, increasing the amount of Litecoin backing each remaining share.

FAQ

Frequently asked questions about LITS stock

How does Ticker Nerd's model rank LITS?

As at 1 Aug 2026, Lite Strategy, Inc. ranks 30 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (85 of 100).

What is the LITS stock forecast for 2030?

No analyst covering Lite Strategy, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LITS are extrapolating price history, which says nothing about the business.

How has LITS stock performed over the past year?

Lite Strategy, Inc. returned -79.9% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Lite Strategy, Inc. do?

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.

What is the latest news on LITS?

The most recent item we track (GlobeNewsWire, 30 July 2026): "Lite Strategy Repurchases 13% of Outstanding Shares Since December, Increasing Litecoin Backing Per Share". Lite Strategy repurchased approximately 4.9 million shares, or 13% of its outstanding shares, under its Share Repurchase Program between December 2025 and July 17, 2026, deploying about $5.4 million at an average price of $1.11 per share through treasury operations.

Company

About Lite Strategy, Inc.

Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer. The company was formerly known as MEI Pharma, Inc. and changed its name to Lite Strategy, Inc. in September 2025. Lite Strategy, Inc. was incorporated in 2000 and is based in San Diego, California.

CEO Mr. Justin J. File CPA · 4 employees · United States · https://www.litestrategy.com